KURA News and Press, Kura Oncology Inc. From 11/04/20

Kura Oncology (KURA) slumps 15% premarket on light volume in apparent reaction to the release on an abstract on leukemia candidate KO-539 that will be presented at the American Society of Hematology ((ASH)) Annual Meeting in early December.Preliminary results from the first three pa...

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2020 financial results before the open...

– Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC – – Company plans to conduct a Phase 1/2 proof-of-concept study of tipifarnib in combination with a PI3Kα inhibitor ...

As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...

SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract reporting preliminary data from KOMET-001, an ongoing c...

Kronos Bio has filed proposed terms for a $175 million U.S. IPO. The firm is advancing a pipeline of treatment candidates for acute myeloid leukemia [AML] and solid tumors. KRON has shown intriguing early trial results and has a significant collaboration relationship with Gilead S...

While the market has mainly sold-off this month, four biotech stocks have showed strength in anticipation of successful drug candidates: Arena Pharmaceuticals (ARNA), Fate Therapeutics (FATE), Kura Oncology (KURA), and Stoke Therapeutics (STOK). The biotech sector has received a lot of at...

SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Stephen Dale, M.D., as Chief Medical Officer. Dr. Dal...

There are two times in a man's life when he should not speculate: when he can't afford it, and when he can. " - Mark Twain Today, we look at a small oncology name with an advancing pipeline. The company has some late-stage compounds. A full analysis is laid out below. Company Overview:...

Kura Oncology, Inc. (KURA) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Pete De Spain - Vice President of Investor Relations Troy Wilson - President & Chief Executive Officer Marc Grasso - Chief Financial Officer & Chief Business Officer ...